PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 14, 2013
- Accepted in final form November 19, 2013
- First Published February 7, 2014.
Article Versions
- Previous version (February 7, 2014 - 13:25).
- You are viewing the most recent version of this article.
Author Disclosures
- Herminia D. Rosas, MD,
- Gheorghe Doros, PhD,
- Sona Gevorkian, MSc,
- Keith Malarick, BS,
- Martin Reuter, PhD,
- Jean-Philippe Coutu, BS,
- Tyler D. Triggs, BS,
- Paul J. Wilkens, BS,
- Wayne Matson, PhD,
- David H. Salat, PhD and
- Steven M. Hersch, MD, PhD
- Herminia D. Rosas, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH NINDS P01 NS058793 NIH, NINDS R01 NS042861
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gheorghe Doros, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sona Gevorkian, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NCCAM, Grant#5U01000613, Project Manager, 2010-2013
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Keith Malarick, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Reuter, PhD,
NONE
NONE
NONE
Frontiers in Brain Imaging Methods (editorial borad, 2013)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NIBIB 5R01EB006758-05 , 2012-2013, Investigator NIH/NCRR 8-P41-EB015896-14, 2012-2013, Investigator NIH/NICHD R01-HD071664-02, 2012-2013, Investigator NIH/NINDS 2-R01-NS042861-06A1, 2012-2013, Investigator NIH/NINDS 5-P01-NS058793-03, 2011-2013, Investigator NIH/NINDS 5R01NS052585-05,2011-2013, Investigator
NONE
NONE
NONE
NONE
NONE
NONE
Siemens, 2010-2013
NONE
- Jean-Philippe Coutu, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen
NIH, R01NR010827, student, 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tyler D. Triggs, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paul J. Wilkens, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wayne Matson, PhD,
NONE
NONE
NONE
NONE
1. (1) gut microbiome molecules as risk factors (2)novel diagnostics for peripheral gut microbiome levels 2. (1)use of metabolic mapping for secondary therapies (2)mathematical technique for discrimination by correlation 3. (1)covalently bound molecules as biomarkers (2)analytical technique for assessing epigenetic factors
NONE
(1)counterpoint health solutions inc., chief scientist,0.16 years.
NONE
NONE
NONE
NONE
(1)prana pharmaceuticals/contract
(1)Wylie Laboratories/NASA contract (2)University of Oslo/Norwegian government/contract (3)Mass General Hospital/NIH/sub contract
NONE
NONE
NONE
NONE
NONE
NONE
counterpoint health solutions inc.,0.16 years
NONE
- David H. Salat, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Janssen Pharmaceuticals
NONE
NONE
NONE
Biogen Idec
NIHNS042861; NIHRRP4114075; NIHR21026104; NIHAG026484; NIHAG028676; R01NR010827;
Executive Committee on Research (MGH)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Steven M. Hersch, MD, PhD
1) Pfizer, DSMB
NONE
NONE
Journal of Huntington's disease, editorial Board 2012- uncompensated.
NONE
NONE
NONE
1) Azevan Pharmaceuticals
NONE
NONE
NONE
PRANA Biotechnology
NIH P01-NS058793....PI NIH U02-AT000613....PI NIH O1NS042861.....investigator NIH UO1-NS071789.....PI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Neurology (H.D.R., S.G., K.M., M.R., T.D.T., P.J.W., S.M.H.), Center for Neuro-imaging of Aging and Neurodegenerative Diseases (H.D.R., S.G., K.M., M.R., J.-P.C., T.D.T., P.J.W., D.H.S.), Athinoula A. Martinos Center for Biomedical Imaging (H.D.R., S.G., K.M., M.R., T.D.T., P.J.W., D.H.S.), and Radiology (H.D.R., M.R.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Biostatistics (G.D.), School of Public Health, Boston University, Boston; Harvard-MIT Division of Health Sciences and Technology (J.-P.C.), Cambridge; and Geriatric Research Education Clinical Center (W.M.), New England Veterans Administration, Bedford, MA.
- Correspondence to Dr. Rosas: rosas{at}helix.mgh.harvard.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.